Preoperative intra-arterial chemotherapy with docetaxel, cisplatin, and peplomycin combined with intravenous chemotherapy using 5-fluorouracil for oral squamous cell carcinoma

The objectives of this study were to evaluate survival in 141 patients with stage II –IV oral squamous cell carcinoma (OSCC) treated with preoperative intra-arterial chemotherapy with docetaxel, cisplatin, and peplomycin combined with intravenous chemotherapy using 5-fluorouracil (IADCPIVF) via the superficial temporal artery, and to clarify the prognostic factors. The study popul ation included 59 patients with stage II OSCC, 34 with stage III, and 48 with stage IV. After IADCPIVF, 139 patients underwent surgery; minimally invasive surgeries (MIS) including excisional biopsy were performed on 96 patients with a remarkably good response to IADCPIVF.
Source: International Journal of Oral and Maxillofacial Surgery - Category: ENT & OMF Authors: Tags: Clinical Paper Source Type: research

Related Links:

AbstractBackgroundPoor oral health is an independent risk factor for upper aerodigestive tract cancers, including esophageal squamous cell carcinoma (ESCC). The pattern recognition receptor Toll-like receptor 4 (TLR4) recognizes lipopolysaccharide in the cell walls of Gram-negative periodontal pathogens associated with the development and progression of ESCC. It is, therefore, plausible that TLR4 plays a crucial role in the pathogenesis of ESCC.MethodsWe used an ESCC tissue microarray to confirm expression of TLR4 in patients with ESCC and to determine whether TLR4 expression status correlates with the clinicopathological ...
Source: Esophagus - Category: Gastroenterology Source Type: research
The aim of this ongoing study was to examine Quality of Life (QoL) and pain in the first three months after trans-oral robotic surgery (TORS). Results will be available in November 2019. With the rising incidence of Human Papilloma Virus (HPV) induced oropharyngeal squamous cell carcinoma (OPSCC) this cancer has become the most frequently diagnosed head and neck cancer world-wide. Currently there are two main treatment options: radiotherapy (with or without chemotherapy) and TORS. TORS is still a relatively new treatment modality (approved by the FDA in 2000) and more research into outcomes, particularly functional and QoL outcomes is needed.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Toxicity, Quality of Life, Survivorship, Costs of Care Source Type: research
Extranodal extension (ENE) in lymphatic metastases from oral cavity squamous cell carcinoma is an adverse prognostic feature that portends a poor prognosis and adverse outcomes. In a pooled analysis of two randomized controlled trials, a therapeutic benefit with the addition of chemotherapy to adjuvant radiotherapy was demonstrated in patients with ENE. The College of American Pathologists have recently recommended classification of ENE by extent of capsular invasion into minor (2mm) ENE.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Poster Theater Presentations Source Type: research
RARITAN, NJ, March 10, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-61186372 (JNJ-6372) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. JNJ-6372 is an EGFR-mesenchymal epithelial transition factor (MET) bispecific antibody that targets activating and resistant EGFR and MET mutations and amplifications.[1]...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Squamous cell carcinoma (SCC) of the tongue is the most common oral cancer. Because of the tongue ’s frequent movement, abundant lymphatic drainage, and rich blood supply, the SCC is prone to regional lymph nodes and distant metastases, and its prognosis is worse than that of the other oral cancers.1 In addition, because of its special location, it and its secondary tissue defect postperativel y may impair the patient’s pronunciation and swallowing. Reliable and stable therapeutic targets can improve the curative effect and reduce the toxic side effects caused by surgery, radiotherapy, and chemotherapy.
Source: The British Journal of Oral and Maxillofacial Surgery - Category: ENT & OMF Authors: Source Type: research
Conclusion: In this study, the combination of Nimotuzumab plus platinum/taxane based chemotherapy was active and well tolerated in Indian patients in R/M SCCHN. Addition of Nimotuzumab to chemotherapy had a response rate of 38.2% and median PFS of 5.2 months are strong arguments for clinically testing this combination.
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
Guanylate-binding protein 1 (GBP1) is a large GTPase of the dynamin superfamily involved in the regulation of membrane, cytoskeleton, and cell cycle progression dynamics. In many cell types, such as endothelial cells and monocytes, GBP1 expression is strongly provoked by interferon γ (IFNγ) and acts to restrain cellular proliferation in inflammatory contexts. In immunity, GBP1 activity is crucial for the maturation of autophagosomes infected by intracellular pathogens and the cellular response to pathogen-associated molecular patterns. In chronic inflammation, GBP1 activity inhibits endothelial cell proliferati...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
ConclusionsIn the OSCC cisplatin-resistant cell lines, NOTCH1, JUN, CTNNB1, CEBPA, and ETS1 were found as the hub genes involved in regulating the cisplatin resistance of OSCC. Members of the miR-200 family may reverse drug resistance of OSCC cells by regulating the hub genes, which can act as potential targets for the treatment of OSCC patients with cisplatin resistance.
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
CONCLUSIONS: LncRNA KCNQ1OT1 promotes the DDP resistance of tongue cancer by sponging miR-124-3p to regulate TRIM14 expression. PMID: 31957833 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
ConclusionsPCE as IC was feasible, with promising efficacy and no effect on compliance with subsequent CRT in unresectable LA ‐SCCHN.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
More News: Cancer & Oncology | Carcinoma | Chemotherapy | Docetaxel | ENT & OMF | Oral Cancer | Skin Cancer | Squamous Cell Carcinoma | Study | Taxotere